172 related articles for article (PubMed ID: 35494006)
1. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.
Hong J; Xia L; Huang Z; Yuan X; Liang X; Dai J; Wu Z; Liang L; Ruan M; Long Z; Cheng X; Chen X; Ni J; Ge J; Li Q; Zeng Q; Xia R; Wang Y; Yang M
Front Oncol; 2022; 12():879471. PubMed ID: 35494006
[TBL] [Abstract][Full Text] [Related]
2. High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity.
Xu L; Xu J; Ma S; Li X; Zhu M; Chen S; Han Y; Tang X; Fu Z; Qiu H; Yu J; Wu D; Wu X
Oncotarget; 2017 Nov; 8(60):102088-102096. PubMed ID: 29254227
[TBL] [Abstract][Full Text] [Related]
3. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
4. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
5. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
6. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.
Tan J; Yu Z; Huang J; Chen Y; Huang S; Yao D; Xu L; Lu Y; Chen S; Li Y
Biomark Res; 2020; 8():6. PubMed ID: 32082573
[TBL] [Abstract][Full Text] [Related]
7. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Dama P; Tang M; Fulton N; Kline J; Liu H
J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
[TBL] [Abstract][Full Text] [Related]
8. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.
Wu Z; Ou J; Liu N; Wang Z; Chen J; Cai Z; Liu X; Yu X; Dai M; Zhou H
Cancer Med; 2023 Apr; 12(7):8956-8969. PubMed ID: 36545697
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
Chajuwan T; Kansuwan P; Kobbuaklee S; Chanswangphuwana C
Leuk Lymphoma; 2022 Feb; 63(2):450-456. PubMed ID: 34585994
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
Wang J; Yang L; Dao FT; Wang YZ; Chang Y; Xu N; Chen WM; Jiang Q; Jiang H; Liu YR; Qin YZ
Leuk Lymphoma; 2022 Jan; 63(1):152-161. PubMed ID: 34405769
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
13. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
[TBL] [Abstract][Full Text] [Related]
14. TIM-3 in Leukemia; Immune Response and Beyond.
Rezaei M; Tan J; Zeng C; Li Y; Ganjalikhani-Hakemi M
Front Oncol; 2021; 11():753677. PubMed ID: 34660319
[TBL] [Abstract][Full Text] [Related]
15. Clinical roles of TIM-3 in myeloid malignancies and its importance in cellular therapy.
Kikushige Y
Blood Cell Ther; 2022 Dec; 5(Spec Edition):S1-S5. PubMed ID: 37220607
[TBL] [Abstract][Full Text] [Related]
16. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
Ge MJ; Xu KL; Xu T; Tang YN; Li ZY; Yan ZL; Sun HY; Cheng H; Zhu F; Sang W; Huang YH; Qiu TT; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931
[TBL] [Abstract][Full Text] [Related]
17. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
18. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
[TBL] [Abstract][Full Text] [Related]
19. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia.
Tan J; Huang S; Huang J; Yu Z; Chen Y; Lu Y; Li Y; Chen S
Asia Pac J Clin Oncol; 2020 Jun; 16(3):137-141. PubMed ID: 32030888
[TBL] [Abstract][Full Text] [Related]
20. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]